Rebif and Diplegia - a phase IV clinical study of FDA data

Summary:

Diplegia is reported as a side effect among people who take Rebif (interferon beta-1a), especially for people who are female, 40-49 old, have been taking the drug for 2 - 5 years also take Ampyra, and have Secondary progressive multiple sclerosis.

The phase IV clinical study analyzes which people have Diplegia when taking Rebif. It is created by eHealthMe based on reports of 60,837 people who have side effects when taking Rebif from the FDA, and is updated regularly.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 61,126 Rebif users. Check the latest studies of Rebif.

What is Diplegia?

Diplegia (paralysis of corresponding parts on both sides of the body) is found to be associated with 240 drugs and 438 conditions by eHealthMe. Check the latest studies of Diplegia.

On Jul, 10, 2026

60,837 people reported to have side effects when taking Rebif.
Among them, 54 people (0.09%) have Diplegia.

Among these 54 people:

How long have people been on Rebif when they have Diplegia? *

What is the gender of people who have Diplegia when taking Rebif? *

female: 70.59 %
male: 29.41 %

What is the age of people who have Diplegia when taking Rebif? *

What are other drugs people take besides Rebif? *

What are other side effects people have besides Diplegia? *

Weakness: 10 people, 18.52%
Pain In Extremity: 8 people, 14.81%
Chills (felling of cold): 7 people, 12.96%
Hypoaesthesia (reduced sense of touch or sensation): 6 people, 11.11%
Fatigue (feeling of tiredness): 6 people, 11.11%
Fall: 5 people, 9.26%
Influenza Like Illness: 5 people, 9.26%
Balance Disorder: 5 people, 9.26%
Gait Disturbance: 5 people, 9.26%
Depression: 4 people, 7.41%

What are the existing conditions these people have? *

Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 5 people, 9.26%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 3.70%
Pain In Extremity: 2 people, 3.70%
Bladder Disorder: 2 people, 3.70%
Vitamin B12 Deficiency: 1 person, 1.85%
Rickets (softening of bones): 1 person, 1.85%
Parkinson's Disease: 1 person, 1.85%
Pain: 1 person, 1.85%
Gait Disturbance: 1 person, 1.85%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 1.85%

* Approximation only. Some reports may have incomplete information.

Do you take Rebif and have Diplegia?

- Check whether Diplegia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Rebif:

Rebif (61,126 reports)

Diplegia treatments and more:

Diplegia (2,474 reports)

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diplegia:

Diplegia (240 drugs)

Browse all the conditions that are associated with Diplegia:

Diplegia (438 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.